



(51) International Patent Classification:

C07K 5/00 (2006.01) A61P 35/00 (2006.01)
A61K 38/00 (2006.01) C07K 14/00 (2006.01)

(21) International Application Number:

PCT/US2022/025087

(22) International Filing Date:

15 April 2022 (15.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/175,826 16 April 2021 (16.04.2021) US

(71) Applicant: **PALLEON PHARMACEUTICALS INC.**
[US/US]; 266 Second Avenue, 2nd Floor, Waltham, Mass-
achusetts 02451 (US).

(72) Inventors: **PENG, Li**; 6 Bicentennial Drive, Lexington,
Massachusetts 02421 (US). **NERLE, Sujata B.**; 31 Sewall
Street, Unit 1, Somerville, Massachusetts 02145 (US). **SID-
DIQUEE, Zakir B.**; 52 Harvey Street, Unit 2, Cambridge,
Massachusetts 02140 (US).

(74) Agent: **GUSTAFSON, Megan A.**; Goodwin Procter LLP,
100 Northern Avenue, IP Docketing Dept/7th Floor,
Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-INFLAMMATORY SIGLEC PROTEINS AND METHODS OF MAKING AND USING SAME

The Siglecs




FIGURE 1

(57) Abstract: The invention relates generally to proteins comprising a recombinant Siglec extracellular domain (ECD), or a functional fragment or variant thereof, optionally containing a mutation that reduces sialic acid binding activity and/or conjugated to a serum half-life enhancer. The invention further relates to methods of using the proteins for treating an inflammatory disorder and/or an autoimmune disorder.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

24 November 2022 (24.11.2022)